<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00565968</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00001344</org_study_id>
    <secondary_id>CDR0000575427</secondary_id>
    <nct_id>NCT00565968</nct_id>
  </id_info>
  <brief_title>Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg</brief_title>
  <official_title>A Phase I Dose Escalation Trial to Evaluate Safety and Efficacy of Oral Sorafenib (Nexavar) With Regional Melphalan Via Normothermic Isolated Limb Infusion (ILI) in Patients With Intransit Extremity Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,&#xD;
      such as melphalan, work in different ways to stop the growth of tumor cells, either by&#xD;
      killing the cells or by stopping them from dividing. Sorafenib may also make tumor cells more&#xD;
      sensitive to melphalan. Giving sorafenib together with an isolated limb infusion of melphalan&#xD;
      may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib when&#xD;
      given together with an isolated limb infusion of melphalan in treating patients with stage&#xD;
      III melanoma of the arm or leg.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the dose-limiting toxicities and maximum tolerate dose of systemic&#xD;
           sorafenib tosylate in combination with regionally administered melphalan by isolated&#xD;
           limb infusion in patients with stage IIIB or IIIC intransit extremity melanoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To characterize the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
        -  To assess the antitumor activity of this regimen, as evidenced by best overall response&#xD;
           and duration of response, in these patients.&#xD;
&#xD;
        -  To characterize the duration of progression-free survival of these patients.&#xD;
&#xD;
        -  To characterize the pharmacokinetics of melphalan.&#xD;
&#xD;
        -  To assess alterations in selected gene and protein expression profiles following&#xD;
           treatment.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of sorafenib tosylate.&#xD;
&#xD;
      Patients receive oral sorafenib tosylate twice daily on days 1-14 and melphalan via isolated&#xD;
      limb infusion into the upper or lower extremities on day 8.&#xD;
&#xD;
      Patients undergo tumor biopsies at baseline and in weeks 2 and 12 for gene expression&#xD;
      analysis and western blot analysis. Patients also undergo blood sample collection&#xD;
      periodically for pharmacokinetic analysis of melphalan.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 1 year and then&#xD;
      every 6 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity, as evidenced by best overall response and duration of response</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of progression-free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of melphalan</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor gene and protein expression profiles following treatment</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>Sorafenib dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <arm_group_label>Sorafenib dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <arm_group_label>Sorafenib dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <arm_group_label>Sorafenib dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
    <arm_group_label>Sorafenib dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>western blotting</intervention_name>
    <arm_group_label>Sorafenib dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>Sorafenib dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary or recurrent extremity melanoma&#xD;
&#xD;
               -  Stage IIIB or IIIC disease&#xD;
&#xD;
                    -  Patients with stage IIIC disease must have had regional lymph nodes&#xD;
                       previously removed&#xD;
&#xD;
          -  Disease to be treated by regional therapy must be distal to the planned site of&#xD;
             tourniquet placement&#xD;
&#xD;
          -  Bidimensionally measurable disease by caliper or radiological method&#xD;
&#xD;
               -  Must have identifiable target lesions for disease assessment&#xD;
&#xD;
                    -  Patients with a single lesion must have archived tumor tissue available for&#xD;
                       research analysis&#xD;
&#xD;
          -  No stage IV disease&#xD;
&#xD;
          -  No known brain metastasis&#xD;
&#xD;
               -  Patients with neurological symptoms must have undergone a CT scan or MRI of the&#xD;
                  brain within the past 4 weeks to exclude brain metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG or Zubrod performance status 0-1&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST ≤ 2.5 x ULN&#xD;
&#xD;
          -  INR &lt; 1.5 or PT/PTT normal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 x ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative serum pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Must have a palpable femoral or axillary pulse in the extremity to be treated&#xD;
&#xD;
          -  No cardiac disease, including any of the following:&#xD;
&#xD;
               -  NYHA class III or IV congestive heart failure&#xD;
&#xD;
               -  Unstable angina (i.e., angina symptoms at rest) or new onset angina within the&#xD;
                  past 3 months&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No cardiac ventricular arrhythmias requiring antiarrhythmic therapy&#xD;
&#xD;
          -  No uncontrolled hypertension, defined as systolic blood pressure (BP) &gt; 150 mm Hg or&#xD;
             diastolic BP &gt; 90 mm Hg, despite optimal medical management&#xD;
&#xD;
          -  No known HIV infection&#xD;
&#xD;
          -  No chronic hepatitis B or C&#xD;
&#xD;
          -  No active clinically serious infection &gt; CTCAE grade 2&#xD;
&#xD;
          -  No thrombotic or embolic events (e.g., cerebrovascular accident or transient ischemic&#xD;
             attacks) within the past 6 months&#xD;
&#xD;
          -  No signs or symptoms of vascular insufficiency (i.e., any history of blood clots or&#xD;
             other ischemic peripheral vascular disease)&#xD;
&#xD;
          -  No evidence or history of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  No pulmonary hemorrhage or bleeding event ≥ CTCAE grade 2 within the past 4 weeks&#xD;
&#xD;
          -  No other hemorrhage or bleeding event ≥ CTCAE grade 3 within the past 4 weeks&#xD;
&#xD;
          -  No serious nonhealing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No significant traumatic injury within the past 4 weeks&#xD;
&#xD;
          -  No condition that impairs the patient's ability to swallow whole pills&#xD;
&#xD;
          -  No malabsorption problem&#xD;
&#xD;
          -  No known history of allergic reactions and/or hypersensitivity to melphalan, sorafenib&#xD;
             tosylate, or any other agent used in the study&#xD;
&#xD;
          -  No psychiatric condition or diminished capacity that would compromise giving informed&#xD;
             consent, or interfere with study compliance&#xD;
&#xD;
          -  No history of other malignancies, except for any of the following:&#xD;
&#xD;
               -  Adequately treated basal cell or squamous cell carcinoma of the skin&#xD;
&#xD;
               -  Curatively treated in situ carcinoma of the uterine cervix, prostate cancer, or&#xD;
                  superficial bladder cancer&#xD;
&#xD;
               -  Other curatively treated solid tumor with no evidence of disease for ≥ 5 years&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  No prior sorafenib tosylate&#xD;
&#xD;
          -  Prior melphalan via isolated limb infusion allowed&#xD;
&#xD;
          -  No antineoplastic therapy, radiotherapy, or any other investigational drug within the&#xD;
             past 4 weeks&#xD;
&#xD;
          -  No major surgery or open biopsy within the past 4 weeks&#xD;
&#xD;
          -  No concurrent Hypericum perforatum (St. John wort) or rifampin&#xD;
&#xD;
          -  Concurrent anti-coagulation treatment with warfarin or heparin allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas S. Tyler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>November 29, 2007</study_first_submitted>
  <study_first_submitted_qc>November 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2007</study_first_posted>
  <last_update_submitted>March 5, 2015</last_update_submitted>
  <last_update_submitted_qc>March 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIB melanoma</keyword>
  <keyword>stage IIIC melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

